These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Flow cytometric detection of HLA-specific antibodies as a predictor of heart allograft rejection. Tambur AR; Bray RA; Takemoto SK; Mancini M; Costanzo MR; Kobashigawa JA; D'Amico CL; Kanter KR; Berg A; Vega JD; Smith AL; Roggero AL; Ortegel JW; Wilmoth-Hosey L; Cecka JM; Gebel HM Transplantation; 2000 Oct; 70(7):1055-9. PubMed ID: 11045642 [TBL] [Abstract][Full Text] [Related]
23. Reduction of alloantibodies via proteasome inhibition in cardiac transplantation. Patel J; Everly M; Chang D; Kittleson M; Reed E; Kobashigawa J J Heart Lung Transplant; 2011 Dec; 30(12):1320-6. PubMed ID: 21968130 [TBL] [Abstract][Full Text] [Related]
24. Donor-specific HLA antibodies after transplantation are associated with deterioration in cardiac function. Leech SH; Mather PJ; Eisen HJ; Pina IL; Margulies KB; Bove AA; Jeevanandam V Clin Transplant; 1996 Dec; 10(6 Pt 2):639-45. PubMed ID: 8996758 [TBL] [Abstract][Full Text] [Related]
25. Combination of Total Lymphoid Irradiation, Low-Dose IVIG and ATG as Rescue Therapy for Highly Sensitized and Antibody-Mediated Rejection Renal Transplant Recipients. Zhu D; Qi G; Tang Q; Li L; Yang C; Lin M; Wu B; Xu M; Cai J; Zhu T; Rong R Clin Transpl; 2014; ():215-21. PubMed ID: 26281148 [TBL] [Abstract][Full Text] [Related]
26. Soluble HLA and anti-idiotypic antibodies in transplantation: modulation of anti-HLA antibodies by soluble HLA antigens from the graft and anti-idiotypic antibodies in renal and cardiac allograft recipients. Suciu-Foca N; Ho E; King DW; Yu YP; Yu-Kai S; Reed E; Cohen D; Brensilver JM; McCabe R; Rose E Transplant Proc; 1991 Feb; 23(1 Pt 1):295-6. PubMed ID: 1990536 [No Abstract] [Full Text] [Related]
28. A novel post-transplant alloantibody surveillance and intervention strategy that improves graft outcomes in sensitized renal transplant recipients. Kimball PM; King A Clin Transpl; 2011; ():369-72. PubMed ID: 22755433 [TBL] [Abstract][Full Text] [Related]
29. Impact of human leukocyte antigen matching and recipients' panel reactive antibodies on two-year outcome in presensitized renal allograft recipients. Meng HL; Jin XB; Li XT; Wang HW; Lü JJ Chin Med J (Engl); 2009 Feb; 122(4):420-6. PubMed ID: 19302748 [TBL] [Abstract][Full Text] [Related]
30. Role of immunoglobulin (Ig)-G and IgM antibodies against donor human leukocyte antigens in organ transplant recipients. Stastny P; Ring S; Lu C; Arenas J; Han M; Lavingia B Hum Immunol; 2009 Aug; 70(8):600-4. PubMed ID: 19375468 [TBL] [Abstract][Full Text] [Related]
31. Persistence of low levels of alloantibody after desensitization in crossmatch-positive living-donor kidney transplantation. Gloor JM; DeGoey S; Ploeger N; Gebel H; Bray R; Moore SB; Dean PG; Stegall MD Transplantation; 2004 Jul; 78(2):221-7. PubMed ID: 15280682 [TBL] [Abstract][Full Text] [Related]
32. Immunoglobulin M-to-immunoglobulin G anti-human leukocyte antigen class II antibody switching in cardiac transplant recipients is associated with an increased risk of cellular rejection and coronary artery disease. Lietz K; John R; Burke E; Schuster M; Rogers TB; Suciu-Foca N; Mancini D; Itescu S Circulation; 2005 Oct; 112(16):2468-76. PubMed ID: 16230499 [TBL] [Abstract][Full Text] [Related]
33. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Jordan SC; Vo A; Bunnapradist S; Toyoda M; Peng A; Puliyanda D; Kamil E; Tyan D Transplantation; 2003 Aug; 76(4):631-6. PubMed ID: 12973100 [TBL] [Abstract][Full Text] [Related]
34. Functional assessment of immune markers of graft rejection: a comprehensive study in live-related donor renal transplantation. Panigrahi A; Deka R; Bhowmik D; Dash SC; Tiwari SC; Guleria S; Mehta SN; Mehra NK Clin Transplant; 2006; 20(1):85-90. PubMed ID: 16556160 [TBL] [Abstract][Full Text] [Related]
35. Impact of IgM and IgG3 anti-HLA alloantibodies in primary renal allograft recipients. Everly MJ; Rebellato LM; Haisch CE; Briley KP; Bolin P; Kendrick WT; Kendrick SA; Morgan C; Maldonado AQ; Harland RC; Terasaki PI Transplantation; 2014 Mar; 97(5):494-501. PubMed ID: 24487396 [TBL] [Abstract][Full Text] [Related]
36. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation. Lee PC; Ozawa M Clin Transpl; 2007; ():219-26. PubMed ID: 18642453 [TBL] [Abstract][Full Text] [Related]
37. Relevance of different antibody detection methods for the prediction of antibody-mediated rejection and deceased-donor kidney allograft survival. Vlad G; Ho EK; Vasilescu ER; Colovai AI; Stokes MB; Markowitz GS; D'Agati VD; Cohen DJ; Ratner LE; Suciu-Foca N Hum Immunol; 2009 Aug; 70(8):589-94. PubMed ID: 19375470 [TBL] [Abstract][Full Text] [Related]
38. Effect of anti-HLA and anti-idiotypic antibodies on the long-term survival of heart and kidney allografts. Reed E; Cohen DJ; Barr ML; Ho E; Marboe CC; Rose EA; Hardy M; Suciu-Foca N Transplant Proc; 1992 Dec; 24(6):2494-5. PubMed ID: 1465842 [TBL] [Abstract][Full Text] [Related]
39. Anti-idiotypic antibodies specific for HLA in heart and kidney allograft recipients. Reed E; Ho E; Cohen DJ; Ramey W; Marboe C; D'Agati V; Rose EA; Hardy M; Suciu-Foca N Immunol Res; 1993; 12(1):1-11. PubMed ID: 8515181 [TBL] [Abstract][Full Text] [Related]
40. Long-term outcomes of kidney transplantation across a positive complement-dependent cytotoxicity crossmatch. Riella LV; Safa K; Yagan J; Lee B; Azzi J; Najafian N; Abdi R; Milford E; Mah H; Gabardi S; Malek S; Tullius SG; Magee C; Chandraker A Transplantation; 2014 Jun; 97(12):1247-52. PubMed ID: 24854670 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]